China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into a partnership agreement with Visen Pharmaceuticals, a joint venture between Denmark’s Ascendis Pharma A/S (NASDAQ: ASND) and Chinese healthcare investment firm Vivo Capital.
Under the terms of the deal, Visen Pharmaceuticals will entrust WuXi Biologics with the manufacturing of both the raw materials and the final product for lonapegsomatropin, TransCon hGH, a once-weekly long-acting growth hormone that is approaching commercialization.- Flcube.com
